U.S. markets closed
  • S&P Futures

    3,364.25
    -18.75 (-0.55%)
     
  • Dow Futures

    27,212.00
    -153.00 (-0.56%)
     
  • Nasdaq Futures

    11,532.50
    -55.50 (-0.48%)
     
  • Russell 2000 Futures

    1,574.30
    -14.70 (-0.93%)
     
  • Crude Oil

    38.66
    -0.91 (-2.30%)
     
  • Gold

    1,908.70
    -3.20 (-0.17%)
     
  • Silver

    24.44
    -0.13 (-0.53%)
     
  • EUR/USD

    1.1786
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    0.7780
    -0.0230 (-2.87%)
     
  • Vix

    33.35
    +0.89 (+2.74%)
     
  • GBP/USD

    1.3034
    -0.0007 (-0.05%)
     
  • USD/JPY

    104.2950
    -0.1990 (-0.19%)
     
  • BTC-USD

    13,798.51
    +43.74 (+0.32%)
     
  • CMC Crypto 200

    272.83
    +11.54 (+4.42%)
     
  • FTSE 100

    5,728.99
    -63.02 (-1.09%)
     
  • Nikkei 225

    23,405.08
    -80.72 (-0.34%)
     

The Fusion Antibodies (LON:FAB) Share Price Has Gained 156%, So Why Not Pay It Some Attention?

Simply Wall St
·3 mins read

The Fusion Antibodies plc (LON:FAB) share price has had a bad week, falling 13%. But that doesn't detract from the splendid returns of the last year. Like an eagle, the share price soared 156% in that time. So we think most shareholders won't be too upset about the recent fall. The real question is whether the business is trending in the right direction.

View our latest analysis for Fusion Antibodies

Given that Fusion Antibodies didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Over the last twelve months, Fusion Antibodies' revenue grew by 78%. That's well above most other pre-profit companies. And the share price has responded, gaining 156% as we previously mentioned. It's great to see strong revenue growth, but the question is whether it can be sustained. The strong share price rise indicates optimism, so there may be a better opportunity for buyers as the hype fades a bit.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. You can see what analysts are predicting for Fusion Antibodies in this interactive graph of future profit estimates.

A Different Perspective

Fusion Antibodies shareholders should be happy with the total gain of 156% over the last twelve months. And the share price momentum remains respectable, with a gain of 148% in the last three months. Demand for the stock from multiple parties is pushing the price higher; it could be that word is getting out about its virtues as a business. It's always interesting to track share price performance over the longer term. But to understand Fusion Antibodies better, we need to consider many other factors. For example, we've discovered 5 warning signs for Fusion Antibodies (1 doesn't sit too well with us!) that you should be aware of before investing here.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on GB exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.